When it comes to equine health, sometimes the best medicine is providing the best information. Boehringer Ingelheim Vetmedica, Inc. (BIVI) has developed a listing of equine vaccines that meet the new U.S. Equine Federation (USEF) requirements for 2016.
“We developed this list to help veterinarians and horse owners understand if their current protocols will keep their horses eligible in USEF competitions,” explained Dr. Rob Keene, BIVI equine technical manager. “We have made a firm commitment to do what’s best for the industry and for horses, and we recognize that veterinarians and horse owners have great choices when it comes to vaccines. We just want to make sure the most accurate and complete information is in their hands.”
In December, the USEF released new regulations that require documentation of a competing horse’s vaccination against equine influenza and equine herpesvirus within the past six months. There are a number of combination and monovalent vaccines available to meet these requirements.
“Boehringer Ingelheim Vetmedica, Inc. is a firm believer in preventive medicine, as we believe it is one of the best ways to keep horses performing at their optimum level,” said Keene. “The USEF regulations will help bring more attention to the role vaccines play in overall horse health.”
For a copy of the comprehensive vaccine chart, contact Cindy Hackmann at firstname.lastname@example.org.
For more information on BIVI’s portfolio of equine vaccines, visit http://www.bi-vetmedica.com/species/equine/products/vetera_vaccines.html#vaccine-line.
Boehringer Ingelheim Vetmedica, Inc., (BIVI) is the fifth largest animal health company in the U.S. and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa. With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11% of net sales of the Animal Health business in R&D. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability. For more information please visit www.bi-vetmedica.com.